Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells.

A number of pathogenic bacterial strains, such as Staphylococcus aureus, are difficult to kill with conventional antibiotics due to intracellular persistence in host airway epithelium. Designing drug delivery systems to deliver potent antimicrobial peptides (AMPs) intracellularly to the airway epithelial cells might thus be a promising approach to combat such infections. In this work, plectasin, which is a cationic AMP of the defensin class, was encapsulated into poly(lactic-co-glycolic acid) (PLGA) nanoparticles using the double emulsion solvent evaporation method. The nanoparticles displayed a high plectasin encapsulation efficiency (71-90%) and mediated release of the peptide over 24h. The antimicrobial efficacy of the peptide-loaded nanoparticles was investigated using bronchial epithelial Calu-3 cell monolayers infected with S. aureus. The plectasin-loaded nanoparticles displayed improved efficacy as compared to non-encapsulated plectasin, while the eukaryotic cell viability was unaffected at the assayed concentrations. Further, the subcellular localization of the nanoparticles was assessed in different relevant cell lines. The nanoparticles were distributed in punctuate patterns intracellularly in Calu-3 epithelial cells and in THP-1 macrophages, whereas A549 epithelial cells did not show significant uptake of the nanoparticles. Overall, encapsulation of plectasin into PLGA-based nanoparticles appears to be a viable strategy to improve the efficacy of plectasin against infections in epithelial tissues.

[1]  J. Veciana,et al.  Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin. , 2012, The Journal of antimicrobial chemotherapy.

[2]  Heikki Peltola,et al.  Acute osteomyelitis in children. , 2014, The New England journal of medicine.

[3]  Bruno Hoen,et al.  Staphylococcus aureus endocarditis: a consequence of medical progress. , 2005, Journal of the American Medical Association (JAMA).

[4]  B. Sinha,et al.  Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus , 2005, Thrombosis and Haemostasis.

[5]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[6]  H. Chambers,et al.  Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Cheung,et al.  Staphylococcus aureus Escapes More Efficiently from the Phagosome of a Cystic Fibrosis Bronchial Epithelial Cell Line than from Its Normal Counterpart , 2006, Infection and Immunity.

[8]  Bhanu Sinha,et al.  Fibronectin‐binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin α5β1 , 1999, Cellular microbiology.

[9]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  Katharina Landfester,et al.  Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. , 2011, ACS nano.

[11]  William R Bishai,et al.  Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. , 2005, The Lancet. Infectious diseases.

[12]  S. Rath,et al.  Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. , 2007, The Journal of antimicrobial chemotherapy.

[13]  Xin-guo Jiang,et al.  Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells. , 2011, International journal of pharmaceutics.

[14]  Kohei Tahara,et al.  Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. , 2009, International journal of pharmaceutics.

[15]  J. Rolland,et al.  Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. , 2012, Nano letters.

[16]  G. Battaglia,et al.  Endocytosis at the nanoscale. , 2012, Chemical Society reviews.

[17]  W. Saltzman,et al.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.

[18]  Simon Benita,et al.  Targeting of nanoparticles to the clathrin-mediated endocytic pathway. , 2007, Biochemical and biophysical research communications.

[19]  P. Tulkens,et al.  Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. , 2006, The Journal of antimicrobial chemotherapy.

[20]  A. Lamprecht,et al.  Effect of the microencapsulation of nanoparticles on the reduction of burst release. , 2007, International journal of pharmaceutics.

[21]  A. Machado,et al.  Characterization of PLGA Microparticles as a Drug Carrier for 3-Ethoxycarbonyl-2H-Benzofuro[3,2-f]-1-Benzopyran-2-One. Ultrastructural Study of Cellular Uptake and Intracellular Distribution , 2006, Drug delivery.

[22]  Elias Fattal,et al.  Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells , 2011, International journal of nanomedicine.

[23]  C. Aranha,et al.  Antimicrobial peptides: premises and promises. , 2004, International journal of antimicrobial agents.

[24]  H Stammer,et al.  Nasal Carriage as a Source of Staphylococcus aureus Bacteremia , 2001 .

[25]  Amandeep Singh,et al.  Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes , 2013, Journal of Cell Science.

[26]  G. Soma,et al.  Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[27]  H. Kristensen,et al.  Antimicrobial peptides effectively kill a broad spectrum of Listeria monocytogenes and Staphylococcus aureus strains independently of origin, sub-type, or virulence factor expression , 2008, BMC Microbiology.

[28]  A. Cheung,et al.  The expression of alpha‐haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT‐1 cells , 2008, Cellular microbiology.

[29]  E. Denkbaş,et al.  Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Robert Bals,et al.  Epithelial antimicrobial peptides in host defense against infection , 2000, Respiratory research.

[31]  F. Stracke,et al.  Influence of Nanoencapsulation on Human Skin Transport of Flufenamic Acid , 2006, Skin Pharmacology and Physiology.

[32]  P. Tulkens,et al.  Restoration of Susceptibility of Intracellular Methicillin-Resistant Staphylococcus aureus to β-Lactams: Comparison of Strains, Cells, and Antibiotics , 2008, Antimicrobial Agents and Chemotherapy.

[33]  J. G. Cory,et al.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. , 1991, Cancer communications.

[34]  Søren Neve,et al.  Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II , 2010, Science.

[35]  Olivier Taboureau,et al.  Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus , 2005, Nature.

[36]  J. Veciana,et al.  Hydrophobic Gentamicin-Loaded Nanoparticles Are Effective against Brucella melitensis Infection in Mice , 2013, Antimicrobial Agents and Chemotherapy.

[37]  H. Swai,et al.  In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[38]  Jayanth Panyam,et al.  Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.

[39]  H. M. Nielsen,et al.  Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[40]  S. Deresinski Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[42]  H. Kristensen,et al.  Plectasin Shows Intracellular Activity against Staphylococcus aureus in Human THP-1 Monocytes and in a Mouse Peritonitis Model , 2009, Antimicrobial Agents and Chemotherapy.

[43]  W. Kelley,et al.  Staphylococcus aureus: new evidence for intracellular persistence. , 2009, Trends in microbiology.

[44]  R. Proctor,et al.  Population Dynamics of Persistent Staphylococcus aureus Isolated from the Airways of Cystic Fibrosis Patients during a 6-Year Prospective Study , 2003, Journal of Clinical Microbiology.

[45]  R. Skov,et al.  Intracellular Activity of Antibiotics against Staphylococcus aureus in a Mouse Peritonitis Model , 2009, Antimicrobial Agents and Chemotherapy.

[46]  Shri Kant,et al.  Polymeric nanoparticulate system: a potential approach for ocular drug delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[47]  Juliane Nguyen,et al.  Biodegradable polymeric nanocarriers for pulmonary drug delivery , 2008 .

[48]  J. Benoit,et al.  Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  Y. Keynan,et al.  Staphylococcus aureus bacteremia, risk factors, complications, and management. , 2013, Critical care clinics.

[50]  P. Tulkens,et al.  Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages , 2003, Antimicrobial Agents and Chemotherapy.

[51]  A. van Belkum,et al.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks , 1997, Clinical microbiology reviews.